CVE-2026-15538A weakness has been identified in primefaces primereact up to 10.9.8.
Updated under an hour ago ()
Does this affect you?
It lists no affected products yet. Add what you run and Signals checks it as products are added.
No exploitation reported and no EPSS estimate yet.
A weakness has been identified in primefaces primereact up to 10.9.8. This issue affects the function ObjectUtils.mutateFieldData of the file components/lib/utils/ObjectUtils.js of the component API. This manipulation of the argument Field causes improperly controlled modification of object prototype attributes. The attack is possible to be carried out remotely. Upgrading to version 10.9.9 and 11.0.0 is capable of addressing this issue. Patch name: 61f182e11d9ef52032ff56f420da763a6938236f. It is recommended to upgrade the affected component.
- CVSS
- 6.3 MEDIUM (v3.1, NVD)CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
- Weakness (CWE)
- CWE-94, CWE-1321
- Known exploited
- Not in CISA's KEV catalog
- EPSS (exploitation in the next 30 days)
- Not loaded for this CVE
- Assigned by
- Not given
- NVD analysis
- Deferred
- Record last updated
- Aug 27, 2026
- First seen by InfoSec Signals
- Oct 9, 2026
Affected products
No affected products are listed yet.
References
- https://github.com/Mantle-UI/mantle-ui/issues/50
- https://github.com/primefaces/primereact/
- https://github.com/primefaces/primereact/commit/61f182e11d9ef52032ff56f420da763a6938236f
- https://github.com/primefaces/primereact/issues/8553
- https://github.com/primefaces/primereact/releases/tag/10.9.9
- https://github.com/primefaces/primereact/security/advisories/GHSA-hgqw-899r-rc46
- https://vuldb.com/cve/CVE-2026-15538
- https://vuldb.com/submit/855024
- https://vuldb.com/vuln/377888
- https://vuldb.com/vuln/377888/cti
The CVE record on cve.org NVD's entry
The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.